SpyGlass Pharma Stifel 2026 Healthcare Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Great. Good morning, everyone. Tom Stephan, Stifel Research. Welcome to day three of the Stifel Healthcare Conference. Patrick, John, thanks so much for joining.
Tom, thanks for having us.
I mean, a lot going on with the company, a lot of good things, so a lot to talk about. I will take a step back and, Patrick, you have been public for six-plus months now, so would love it if you could start by reflecting on the team's execution and what you have accomplished in 2026, kind of to set the stage here.
Yeah. Thanks, Tom. 2026, no different than I would say the other prior six years, if you will. Company formed in 2019, and every year has been about one foot in front of the other, executing. As you know, we had four private raises, all up rounds. We were planning for the IPO earlier this year. That was always the mission. Our intent is to make sure that BIM-IOL gets to market and gets to as many patients as possible. This year was specifically about executing, first with the financing, delivering on our catalysts. You saw us release four-year data. We had an acquisition we announced last month, which bolsters our supply chain and scalability. Then, as you saw just yesterday, we announced initiation of BIM-DRS, our second-generation system.
For me, this is just a capital T on the timing and execution, and this company continues to do that.
That's fantastic. You touched on pretty much all the topics that I want to dig deeper into, and I'll start with the four-year first-in-human data. Patrick, on that, start by talking about the relevance for SpyGlass and just how investors should be interpreting that.
I think the four-year data is groundbreaking, is a great way to describe it. There's several technologies in market today, but nothing we've seen to date can show and suggest durability out to four years. We've now done that with the BIM-IOL System. It's our first-in-human trial, and so it's a small N, a single site, but I think it speaks to the potential of a system that can provide durable safety and efficacy out to four years. I think it speaks to our ability to control the elution profile. We've been public and very proud of our in vitro release curves. We've shown that, and I think it proves that the technological capability is there to elute consistently over years. Now the proof is in the pudding.
To be able to come out with four-year data with 86% of our patients still off of all topical medicine at four years, it's unheard of. I think we're in a category of our own. Clearly, patients and surgeons need more options, and we're excited for what this represents for the potential of BIM-IOL in market someday.
Got it. That's fantastic. Maybe to provide some further context, BIM-IOL that's in phase III now, it still has three years of drug payload. Is that correct? If so, do we think about the four-year data, you kind of mentioned this, Patrick, as sort of elution control and the proof in the pudding. Do we think about the data maybe more as proving out your sustained release drug delivery capabilities that, at the end of the day, is one of your core competencies?
Yeah. It absolutely does. It proves that we can go for extended periods of duration. You're right. Our phase III product does have three years of payload in that product. Years ago, when we asked surgeons, "What's your minimally viable product? How long do you need this product to work for?" 95% of them said, "six to 12 months." We thought, "Well, that's nice. It's not good enough for us." two years felt better, and surgeons said yes. Three years felt even better, but they started to not believe that it's even possible to get to three years.
When we talked to the FDA, they said, "As long as you have product, you're going to need to follow these patients." Years ago, as a small private company, the idea of a seven- to 10-year trial was a bit tenuous, and so we thought three years was meaningful. Surgeons, it was 3X their MVP, and it was something that we could start with. Yes, BIM-IOL, our phase III patients does have a three-year payload. That's our intended first commercial dose. But I think the four-year data speaks to the potential even beyond three years with subsequent releases.
Yep. Absolutely. We'll touch on that shortly. Sticking with the four-year first-in-human data, we'll talk about the IOL later, for sure. But, Patrick, it'd be helpful if you could contextualize the four-year visual acuity data, and hopefully I have this right, how that 90% of patients at 20/25 or better should be viewed by investors.
I think it speaks to the quality of the material that we're using. Surgeons want to be able to rely and trust that when they tell a patient, "I can get you here," they can deliver those refractive outcomes post-operatively. They have that comfort with the existing commercial lenses that they're implanting today. We knew long ago that surgeons were going to look for that same quality and confidence in our lens. As you saw just recently, we acquired Advanced Vision Science, the manufacturer of our lens. Prior to that announcement, it wasn't public in terms of who was actually manufacturing our lens. We told surgeons, "This is a quality lens. It's the state-of-the-art monomers that everyone else is using.
It's FDA-approved materials." They trusted us, and now they understand where the material comes from, but it speaks to the quality of lens that we're already able to produce, and that bodes confidence for surgeons so that when they're implanting SpyGlass, hopefully commercially someday, that they can have that same confidence going into the surgery with the patient that they can deliver the same refractive outcomes.
Absolutely. Fantastic. We'll dig into that a little more later on. To wrap up here on the BIM-IOL first-in-human study, I believe the follow-up intent is out to seven years, if I have that correct. Should we be on the lookout next year for five-year data?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
